Trial Profile

Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 02 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belimumab (Primary)
Indications Systemic lupus erythematosus
Focus Therapeutic Use
Acronyms BLAST

Most Recent Events

15 Nov 2023 Results assessing systemic lupus (SLE) patients prior to treatment who will respond favorably to belimumab treatment, were presented at the ACR Convergence 2023.
03 Jun 2023 Results (n=24) assessing examination of gene expression variables in SLE patients prior to belimumab treatment with limited background medications in order to distinguish those who subsequently respond from those who do not, presented at the 24th Annual Congress of the European League Against Rheumatism
06 Dec 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com